Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
$74.57M
Mr. James V. Caruso
12.00
Florham Park, NJ
May 20, 2005
-0.67
$-3.09
2.46
2.54
-15,432.54%
-1.42
-0.02
2.76
266.94
2.46
-118.82%
-1,855.60%
Similar stocks (12)
Longboard Pharmaceuticals, Inc.
LBPH
Capricor Therapeutics, Inc.
CAPR
Benitec Biopharma Inc.
BNTC
Aileron Therapeutics, Inc.
ALRN
NextCure, Inc.
NXTC
Lumos Pharma, Inc.
LUMO
Bolt Biotherapeutics, Inc.
BOLT
EOM Pharmaceuticals Holdings, Inc.
IMUC
Monopar Therapeutics Inc.
MNPR
Tenax Therapeutics, Inc.
TENX
Pulmatrix, Inc.
PULM
Bio-Path Holdings, Inc.
BPTH
ETF Exposure (11)
iShares Micro-Cap ETF
IWC
0.01993%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (12)
Longboard Pharmaceuticals, Inc.
LBPH
Capricor Therapeutics, Inc.
CAPR
Benitec Biopharma Inc.
BNTC
Aileron Therapeutics, Inc.
ALRN
NextCure, Inc.
NXTC
Lumos Pharma, Inc.
LUMO
Bolt Biotherapeutics, Inc.
BOLT
EOM Pharmaceuticals Holdings, Inc.
IMUC
Monopar Therapeutics Inc.
MNPR
Tenax Therapeutics, Inc.
TENX
Pulmatrix, Inc.
PULM
Bio-Path Holdings, Inc.
BPTH
ETF Exposure (11)
iShares Micro-Cap ETF
IWC
0.01993%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%